{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T04:17:24Z","timestamp":1771993044990,"version":"3.50.1"},"reference-count":44,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T00:00:00Z","timestamp":1625011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Applied Sciences"],"abstract":"<jats:p>The breast cancer therapies available are insufficient, especially since first-line treatments, such as paclitaxel, result in drug resistance and their toxicity often limits their concentration. Strategies like drug repurposing are beneficial, and novel treatments can emerge by repurposing drugs that interfere with the dopamine and serotonin receptors, and thus influence tumor growth. In this study, the MTT assay was used to test the efficacy of such repurposed drugs commonly used for neurodegenerative disorders that act on the dopamine and serotonin receptors to reduce the MCF-7 cell\u2019s viability, either by their single use or in combination with the reference drug paclitaxel. Furthermore, the expression of vimentin and E-cadherin was assayed by immunofluorescence. The dopamine receptor-altering drugs benztropine and thioridazine resulted in the strongest reduction of cell viability when combined with paclitaxel, which may be connected to the alteration of E-cadherin rather than vimentin expression. More studies are needed to understand the mechanism of action of the combinations tested and the efficacious role of dopamine and serotonin.<\/jats:p>","DOI":"10.3390\/app11136082","type":"journal-article","created":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T10:03:19Z","timestamp":1625047399000},"page":"6082","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["New Insight into Breast Cancer Cells Involving Drug Combinations for Dopamine and Serotonin Receptors"],"prefix":"10.3390","volume":"11","author":[{"given":"B\u00e1rbara","family":"Costa","sequence":"first","affiliation":[{"name":"OncoPharma Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Dr. Pl\u00e1cido da Costa, 4200-450 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9186-3711","authenticated-orcid":false,"given":"Rita","family":"Matos","sequence":"additional","affiliation":[{"name":"Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar, University of Porto (ICBAS-UP), Rua Jorge Viterbo Ferreira 228, 4050-513 Porto, Portugal"},{"name":"i3S, Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, University of Porto, Rua Alfredo Allen 208, 4200-135 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2305-1631","authenticated-orcid":false,"given":"Irina","family":"Amorim","sequence":"additional","affiliation":[{"name":"Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar, University of Porto (ICBAS-UP), Rua Jorge Viterbo Ferreira 228, 4050-513 Porto, Portugal"},{"name":"i3S, Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, University of Porto, Rua Alfredo Allen 208, 4200-135 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5302-0086","authenticated-orcid":false,"given":"F\u00e1tima","family":"G\u00e4rtner","sequence":"additional","affiliation":[{"name":"i3S, Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, University of Porto, Rua Alfredo Allen 208, 4200-135 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1283-1042","authenticated-orcid":false,"given":"Nuno","family":"Vale","sequence":"additional","affiliation":[{"name":"OncoPharma Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Dr. Pl\u00e1cido da Costa, 4200-450 Porto, Portugal"},{"name":"Department of Community Medicine, Information and Health Decision Sciences (MEDCIDS), Faculty of Medicine, University of Porto, Rua Dr. Pl\u00e1cido da Costa, s\/n, 4200-450 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2021,6,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0749-2081(16)30035-3","article-title":"Overview of Paclitaxel (TAXOL\u00ae)","volume":"9","author":"Martin","year":"1993","journal-title":"Semin. Oncol. Nurs."},{"key":"ref_2","first-page":"1","article-title":"Breast cancer","volume":"5","author":"Harbeck","year":"2019","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Abu Samaan, T.M., Samec, M., Liskova, A., Kubatka, P., and B\u00fcsselberg, D. (2019). Paclitaxel\u2019s Mechanistic and Clinical Effects on Breast Cancer. Biomolecules, 9.","DOI":"10.3390\/biom9120789"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1517\/14740338.6.5.609","article-title":"Paclitaxel: A review of adverse toxicities and novel delivery strategies","volume":"6","author":"Marupudi","year":"2007","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s40262-017-0563-z","article-title":"Clinical Pharmacokinetics of Paclitaxel Monotherapy: An Updated Literature Review","volume":"57","author":"Stage","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"500","DOI":"10.3389\/fonc.2018.00500","article-title":"The Influence of Metabolism on Drug Response in Cancer","volume":"8","author":"Zaal","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Cree, I.A., and Charlton, P. (2017). Molecular chess? Hallmarks of anti-cancer drug resistance. BMC Cancer, 17.","DOI":"10.1186\/s12885-016-2999-1"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3389\/fphar.2013.00057","article-title":"Systemic cancer therapy: Achievements and challenges that lie ahead","volume":"4","author":"Palumbo","year":"2013","journal-title":"Front. Pharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1158\/0008-5472.CAN-08-4289","article-title":"Catecholamines Regulate Tumor Angiogenesis: Figure 1","volume":"69","author":"Chakroborty","year":"2009","journal-title":"Cancer Res."},{"key":"ref_10","first-page":"1543","article-title":"Roles of dopamine receptors and their antagonist thioridazine in hepatoma metastasis","volume":"8","author":"Lu","year":"2015","journal-title":"OncoTargets Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.bcp.2015.03.013","article-title":"Dopamine enhances the response of sunitinib in the treatment of drug-resistant breast cancer: Involvement of eradicating cancer stem-like cells","volume":"95","author":"Wang","year":"2015","journal-title":"Biochem. Pharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1158\/1078-0432.CCR-07-1778","article-title":"Dopamine Increases the Efficacy of Anticancer Drugs in Breast and Colon Cancer Preclinical Models","volume":"14","author":"Sarkar","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1593\/neo.81630","article-title":"Depletion of Serotonin and Selective Inhibition of 2B Receptor Suppressed Tumor Angiogenesis by Inhibiting Endothelial Nitric Oxide Synthase and Extracellular Signal-Regulated Kinase 1\/2 Phosphorylation","volume":"11","author":"Asada","year":"2009","journal-title":"Neoplasia"},{"key":"ref_14","first-page":"243","article-title":"5-HT serotonin receptors modulate mitogenic signaling and impact tumor cell viability","volume":"9","author":"Ballou","year":"2018","journal-title":"Mol. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"89","DOI":"10.21037\/atm.2018.01.01","article-title":"Tumor progression: The neuronal input","volume":"6","author":"Arese","year":"2018","journal-title":"Ann. Transl. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.drup.2014.09.001","article-title":"Dopamine and serotonin regulate tumor behavior by affecting angiogenesis","volume":"17","author":"Peters","year":"2014","journal-title":"Drug Resist. Updat."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.drudis.2006.11.008","article-title":"Multi-target therapeutics: When the whole is greater than the sum of the parts","volume":"12","author":"Zimmermann","year":"2007","journal-title":"Drug Discov. Today"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"38022","DOI":"10.18632\/oncotarget.16723","article-title":"Combination therapy in combating cancer","volume":"8","author":"Mokhtari","year":"2017","journal-title":"Oncotarget"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s10555-019-09840-2","article-title":"Drug repurposing towards targeting cancer stem cells in pediatric brain tumors","volume":"39","author":"Bahmad","year":"2020","journal-title":"Cancer Metastasis Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-55145-3","article-title":"Selective Effects of Thioridazine on Self-Renewal of Basal-Like Breast Cancer Cells","volume":"9","author":"Tegowski","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1038\/onc.2015.369","article-title":"Expression and therapeutic targeting of dopamine receptor-1 (D1R) in breast cancer","volume":"35","author":"Borcherding","year":"2016","journal-title":"Oncogene"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1111\/bcp.13661","article-title":"Use of antipsychotics and risk of breast cancer: A Danish nationwide case\u2013control study","volume":"84","author":"Lash","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/npp.2014.214","article-title":"Evidence that formulations of the selective MAO-B inhibitor, selegiline, which bypass first-pass metabolism, also inhibit MAO-A in the human brain","volume":"40","author":"Fowler","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.18632\/oncotarget.13537","article-title":"New use of an old drug: Inhibition of breast cancer stem cells by benztropine mesylate","volume":"8","author":"Cui","year":"2016","journal-title":"Oncotarget"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e0003","DOI":"10.5041\/RMMJ.10003","article-title":"Pharmacology of Rasagiline, a New MAO-B Inhibitor Drug for the Treatment of Parkinson\u2019s Disease with Neuroprotective Potential","volume":"1","author":"Finberg","year":"2010","journal-title":"Rambam Maimonides Med. J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.3892\/or.2013.2635","article-title":"Effects of the monoamine oxidase inhibitors pargyline and tranylcypromine on cellular proliferation in human prostate cancer cells","volume":"30","author":"Lee","year":"2013","journal-title":"Oncol. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1038\/sj.bjp.0703747","article-title":"Pharmacological characterization of the 5-HT receptor-mediated contraction in the mouse isolated ileum","volume":"131","author":"Tuladhar","year":"2000","journal-title":"Br. J. Pharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13104-015-1000-8","article-title":"Limitations of the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay when compared to three commonly used cell enumeration assays","volume":"8","author":"Joubert","year":"2015","journal-title":"BMC Res. Notes"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/bjc.1993.488","article-title":"Cytotoxic studies of paclitaxel (Taxol\u00ae) in human tumour cell lines","volume":"68","author":"Liebmann","year":"1993","journal-title":"Br. J. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3892\/ol.2011.416","article-title":"Sensitization of breast cancer cells to taxol by inhibition of taxol resistance gene 1","volume":"3","author":"Bai","year":"2011","journal-title":"Oncol. Lett."},{"key":"ref_32","first-page":"3147","article-title":"The Story of MCF-7 Breast Cancer Cell Line: 40 years of Experience in Research","volume":"35","author":"Cimpean","year":"2015","journal-title":"Anticancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/cpch.21","article-title":"Measuring Cancer Drug Sensitivity and Resistance in Cultured Cells","volume":"9","author":"Niepel","year":"2017","journal-title":"Curr. Protoc. Chem. Biol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Aslant\u00fcrk, \u00d6.S. (2018). In Vitro Cytotoxicity and Cell Viability Assays: Principles, Advantages, and Disadvantages, IntechOpen.","DOI":"10.5772\/intechopen.71923"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"M\u00e9ry, B., Guy, J.-B., Vallard, A., Espenel, S., Ardail, D., Rodriguez-Lafrasse, C., Rancoule, C., and Magn\u00e9, N. (2017). In Vitro Cell Death Determination for Drug Discovery: A Landscape Review of Real Issues. J. Cell Death, 10.","DOI":"10.1177\/1179670717691251"},{"key":"ref_36","first-page":"839","article-title":"Circumvention of Multiple-Drug Resistance in Human Cancer Cells by Thioridazine, Trifluoperazine, and Chlorpromazine2","volume":"76","author":"Kuwano","year":"1986","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"15977","DOI":"10.1074\/jbc.RA118.003719","article-title":"Thioridazine inhibits self-renewal in breast cancer cells via DRD2-dependent STAT3 inhibition, but induces a G1 arrest independent of DRD2","volume":"293","author":"Tegowski","year":"2018","journal-title":"J. Biol. Chem."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Sogawa, C., Eguchi, T., Tran, M.T., Ishige, M., Trin, K., Okusha, Y., Taha, E.A., Lu, Y., Kawai, H., and Sogawa, N. (2020). Antiparkinson Drug Benztropine Suppresses Tumor Growth, Circulating Tumor Cells, and Metastasis by Acting on SLC6A3\/DAT and Reducing STAT3. Cancers, 12.","DOI":"10.20944\/preprints202002.0003.v1"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40478-019-0657-y","article-title":"Preventive action of benztropine on platinum-induced peripheral neuropathies and tumor growth","volume":"7","author":"Cerles","year":"2019","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"4545","DOI":"10.2147\/IJN.S104635","article-title":"Codelivery of thioridazine and doxorubicin using nanoparticles for effective breast cancer therapy","volume":"11","author":"Luo","year":"2016","journal-title":"Int. J. Nanomed."},{"key":"ref_41","first-page":"925","article-title":"The mass-action law based algorithm for cost-effective approach for cancer drug discovery and development","volume":"1","author":"Chou","year":"2011","journal-title":"Am. J. Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1096\/fj.09-151639","article-title":"Vimentin induces changes in cell shape, motility, and adhesion during the epithelial to mesenchymal transition","volume":"24","author":"Mendez","year":"2010","journal-title":"FASEB J."},{"key":"ref_43","first-page":"5190","article-title":"Loss of epithelial markers and acquisition of vimentin expression in adri-amycin- and vinblastine-resistant human breast cancer cell lines","volume":"52","author":"Sommers","year":"1992","journal-title":"Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1200\/JCO.2011.37.6418","article-title":"Development of Therapeutic Combinations Targeting Major Cancer Signaling Pathways","volume":"31","author":"Yap","year":"2013","journal-title":"J. Clin. Oncol."}],"container-title":["Applied Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3417\/11\/13\/6082\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:23:55Z","timestamp":1760163835000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3417\/11\/13\/6082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,30]]},"references-count":44,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2021,7]]}},"alternative-id":["app11136082"],"URL":"https:\/\/doi.org\/10.3390\/app11136082","relation":{},"ISSN":["2076-3417"],"issn-type":[{"value":"2076-3417","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,30]]}}}